Veliparib ER is under clinical development by AbbVie and currently in Phase II for Essential Thrombocythemia. According to GlobalData, Phase II drugs for Essential Thrombocythemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Veliparib ER LoA Report. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Veliparib ER overview

Veliparib (ABT-888) is under development for the treatment of metastatic adenocarcinoma of the pancreas, anaplastic astrocytoma, relapsed or refractory and newly diagnosed acute myeloid leukemia, chronic myelocytic leukemia, polycythemia vera, myelofibrosis, essential thrombocythemia, myeloproliferative disorders and glioblastoma multiforme (GBM). It is administered through oral route in the form of extended-release capsule. It acts by targeting PARP.
The drug candidate was also under development for the treatment of epithelial ovarian cancer, triple-negative breast cancer, squamous non-small cell lung cancer, fallopian tube cancer, peritoneal cancer, rectal cancer, gastric cancer, relapsed and refractory multiple myeloma, human epidermal growth factor receptor 2 negative breast cancer, metastatic breast cancer, castration-resistant prostate cancer, testicular cancer, germ cell tumors, germinomatous germ cell tumors, nongerminomatous germ cell tumors, hepatocellular carcinoma, diffuse large b-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, small-cell lung cancer, pancreatic cancer, biliary tumor, transitional cell cancer (urothelial cell cancer), Brenner tumor, endometrial cancer, clear cell squamous cell carcinoma ,esophageal cancer, prostate cancer, acute promyelocytic leukemia, acute lymphocytic leukemia, metastatic melanoma, non-small cell lung cancer, natural killer cell lymphomas, t-cell lymphomas, head and neck squamous cell carcinoma, cervical cancer, refractory brain metastasis, and oropharyngeal cancer. 

AbbVie overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers. The company has operations in the Americas, Asia-Pacific, Europe, the Middle East and Africa. AbbVie is headquartered in North Chicago, Illinois, the US.

For a complete picture of Veliparib ER’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.